These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 15656613)
1. 14-azacamptothecin: a potent water-soluble topoisomerase I poison. Cheng K; Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM J Am Chem Soc; 2005 Jan; 127(3):838-9. PubMed ID: 15656613 [TBL] [Abstract][Full Text] [Related]
2. Luotonin A. A naturally occurring human DNA topoisomerase I poison. Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biochemical properties of E-ring modified luotonin A derivatives. Cagir A; Jones SH; Eisenhauer BM; Gao R; Hecht SM Bioorg Med Chem Lett; 2004 May; 14(9):2051-4. PubMed ID: 15080977 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of 14-azacamptothecin, a water-soluble topoisomerase I poison. Rahier NJ; Cheng K; Gao R; Eisenhauer BM; Hecht SM Org Lett; 2005 Mar; 7(5):835-7. PubMed ID: 15727453 [TBL] [Abstract][Full Text] [Related]
5. Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons. Rahier NJ; Eisenhauer BM; Gao R; Jones SH; Hecht SM Org Lett; 2004 Feb; 6(3):321-4. PubMed ID: 14748583 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 10,11-methylenedioxy-14-azacamptothecin. Elban MA; Sun W; Eisenhauer BM; Gao R; Hecht SM Org Lett; 2006 Aug; 8(16):3513-6. PubMed ID: 16869648 [TBL] [Abstract][Full Text] [Related]
7. On the role of E-ring oxygen atoms in the binding of camptothecin to the topoisomerase I-DNA covalent binary complex. Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM Bioorg Med Chem; 2005 Feb; 13(4):1381-6. PubMed ID: 15670945 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Nacro K; Zha CC; Guzzo PR; Jason Herr R; Peace D; Friedrich TD Bioorg Med Chem; 2007 Jun; 15(12):4237-46. PubMed ID: 17418582 [TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354 [TBL] [Abstract][Full Text] [Related]
11. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity. Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and topoisomerase I inhibitory properties of luotonin A analogues. Cagir A; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM Bioorg Med Chem; 2004 Dec; 12(23):6287-99. PubMed ID: 15519171 [TBL] [Abstract][Full Text] [Related]
13. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322 [TBL] [Abstract][Full Text] [Related]
15. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Fu Q; Kim SW; Chen HX; Grill S; Cheng YC Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and cytotoxic activity of substituted luotonin A derivatives. Dallavalle S; Merlini L; Beretta GL; Tinelli S; Zunino F Bioorg Med Chem Lett; 2004 Dec; 14(23):5757-61. PubMed ID: 15501036 [TBL] [Abstract][Full Text] [Related]
17. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535 [TBL] [Abstract][Full Text] [Related]
18. Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin. Tangirala RS; Dixon R; Yang D; Ambrus A; Antony S; Agama K; Pommier Y; Curran DP Bioorg Med Chem Lett; 2005 Nov; 15(21):4736-40. PubMed ID: 16140529 [TBL] [Abstract][Full Text] [Related]
19. Effects of modification of the active site tyrosine of human DNA topoisomerase I. Gao R; Zhang Y; Dedkova L; Choudhury AK; Rahier NJ; Hecht SM Biochemistry; 2006 Jul; 45(27):8402-10. PubMed ID: 16819839 [TBL] [Abstract][Full Text] [Related]
20. Novel camptothecin derivatives as topoisomerase I inhibitors. Basili S; Moro S Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]